Dr. Benjamin Bikman earned his Ph.D. in Bioenergetics and was a postdoctoral fellow with the Duke-National University of Singapore in metabolic disorders. He is currently a professor of pathophysiology and a biomedical scientist at Brigham Young University in Utah.
Dr. Bikman's professional focus as a scientist and professor is to better understand chronic modern-day diseases, with a special emphasis on the origins and consequences of obesity and diabetes, with an increasing scrutiny of the pathogenicity of insulin and insulin resistance. He frequently publishes his research in peer-reviewed journals and presents at international science meetings.
summerizer
Opening and metabolic problem
- Ben Bikman is a biomedical scientist focused on metabolic disorders, and the talk covers GLP-1 drugs, their consequences, and their use.
- The worldwide rise in overweight, obesity, and insulin resistance is the metabolic problem that makes GLP-1 drugs relevant.
- Insulin resistance affects more than half of adults worldwide and contributes to many plagues of prosperity.
Fat-cell biology and weight loss
- Fat mass expands through larger fat cells, more fat cells, or both; the usual human pattern is hypertrophy.
- Hypertrophic fat cells become insulin resistant because they run out of room to keep storing fat under insulin.
- Large fat cells also become hypoxic, pro-inflammatory, and leaky with free fatty acids, which drives whole-body insulin resistance.
- Metabolic weight loss means shrinking fat cells by reducing energy and reducing insulin.
- Carbohydrate control and structured fasting lower insulin and help shrink fat cells, while simple calorie cutting plus exercise increases hunger.
Why GLP-1 became a drug target
- The gut is a major endocrine organ, and incretins are gut hormones tied to blood-glucose control.
- Gastric bypass data make GLP-1 central because diabetes markers can improve within about one week before major fat loss.
- GLP-1 slows intestinal movement, signals the brain to reduce hunger, stimulates fat-cell lipolysis, supports ketogenesis, and suppresses glucagon.
- GLP-1-based glutide drugs began as anti-diabetic medications because glucagon suppression lowers blood glucose; weight loss was initially a modest side effect.
High-dose consequences
- The weight-loss versions are higher-dose versions of diabetes drugs, so the intestines can be slowed too much.
- Excess gut slowing can reach intestinal paralysis, and body-weight loss can include substantial lean mass along with fat mass.
- After stopping a GLP-1 drug, weight often returns, while lost lean mass may not return as readily, leaving a higher body-fat percentage.
- Real-world persistence is poor: US and UK type 2 diabetes data show roughly two-thirds to 70% discontinuation by 24 months.
Insulin, fat-cell number, and receptor pressure
- The idea that GLP-1 drugs disprove insulin control of fat storage is inaccurate; whole-body studies show insulin secretion can fall during GLP-1 exposure after meals.
- GLP-1 agonists may also move preadipocytes toward differentiation, which can mean smaller fat cells during active weight loss but more capacity for later fat regain.
- Chronic GLP-1 receptor agonism can make receptors less responsive and may lower endogenous GLP-1 production.
Drug combinations and food-based GLP-1 release
- The next wave of obesity drugs pairs GLP-1 action with other appetite signals such as amylin, while muscle-preservation drugs are being tested for lean-mass loss.
- Endogenous GLP-1 can be increased with soluble fiber, yerba mate, allulose, protein, and natural fats.
- Saturated and monounsaturated natural fats produced much stronger GLP-1 responses than refined seed oil in the fat-comparison data, and recent low-carbohydrate meal data showed about triple the GLP-1 response of a low-fat meal.
Practical stance
- Lower-dose GLP-1 drugs were more favorable, but higher-dose use makes dose the key issue.
- The best use is the lowest effective dose under clinician guidance, especially where severe carbohydrate addiction blocks dietary control.
- Any GLP-1 use belongs with structured resistance exercise and nutrient priority: essential amino acids and essential fats come first, while essential carbohydrates do not exist.
- When appetite is low, focus on fats and prioritize protein.
References [11:29] Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes — https://doi.org/10.1097/SLA.0b013e3181efc49a [13:49] Incretin Levels and Effect Are Markedly Enhanced 1 Month After Roux-en-Y Gastric Bypass Surgery in Obese Patients With Type 2 Diabetes — https://doi.org/10.2337/dc06-1549 [17:49] Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study — https://doi.org/10.1210/jendso/bvab048.030 [18:37] Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension — https://doi.org/10.1111/dom.14725 [19:48] Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States — https://doi.org/10.2147/PPA.S277676 [19:48] Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK — https://doi.org/10.1136/bmjdrc-2021-002517 [22:30] Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes — https://doi.org/10.1210/jc.2003-030049 [25:03] GLP-1/GLP-1R Signaling in Regulation of Adipocyte Differentiation and Lipogenesis — https://doi.org/10.1159/000478872 [27:22] Chronic Exposure to GLP-1R Agonists Promotes Homologous GLP-1 Receptor Desensitization In Vitro but Does Not Attenuate GLP-1R-Dependent Glucose Homeostasis In Vivo — https://doi.org/10.2337/diabetes.53.suppl_3.S205 [27:49] Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial — https://doi.org/10.1111/dom.14242 [28:47] Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial — https://doi.org/10.1016/S0140-6736(21)00845-X [30:33] Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review — https://doi.org/10.1186/s12986-016-0153-3 [30:37] Mate tea (Ilex paraguariensis) promotes satiety and body weight lowering in mice: involvement of glucagon-like peptide-1 — https://doi.org/10.1248/bpb.34.1849 [30:46] GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose — https://doi.org/10.1038/s41467-017-02488-y [32:40] The Effect on Glucagon, Glucagon-Like Peptide-1, Total and Acyl-Ghrelin of Dietary Fats Ingested with and without Potato — https://doi.org/10.1210/jc.2009-2559